A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BYS, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo SP.
Cohn AL, et al. Among authors: sakaeva dd.
Ann Oncol. 2013 Jul;24(7):1777-1785. doi: 10.1093/annonc/mdt057. Epub 2013 Mar 19.
Ann Oncol. 2013.
PMID: 23510984
Free article.
Clinical Trial.